The market appears to be deeply concerned about the impact of generics on each of these drugmaker's top-lines moving forward. Amgen, for instance, is facing the threat of biosimilar competition to its white-blood cell …
The Motley Fool · 11/22/2015
Dividend Stock
NEW YORK (TheStreet) -- Amgen (AMGN - Get Report) stock is up 1.73% to $162.67 in early afternoon trading on Monday, after CVS Health (CVS) announced that it would carry Amgen's cholesterol-lowering injections.
The Street · 11/23/2015
CVS Health
Amgen (NASDAQ:AMGN) was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating in a report released on Monday, reports. They currently have a $168.73 price objective on the medical research … · 1 day ago
More from Bing News
Amgen is a Zacks Rank #3 (Hold) stock. A better-ranked stock in the health care sector is Baxalta Incorporated BXLT, which carries a Zacks Rank #1 (Strong Buy).
NASDAQ · 11/24/2015
CVS formulary
They presently have a $168.73 price target on the medical research company’s stock. Vetr‘s price objective indicates a potential upside of 3.85% from the company’s current price. Shares of Amgen (NASDAQ …
Ticker Report · 11/24/2015
[PR Newswire] – THOUSAND OAKS, Calif., Nov. 23, 2015 /PRNewswire/ — Amgen (AMGN) today announced that CVS Health will provide preferred access to Repatha® (evolocumab) through its CVS/caremark …
Jutia Group · 11/23/2015
Amgen gained as CVS sealed the deal to sell Repatha Amgen (AMGN ... AMGN closed at $162.47 and was trading at 3.9% above its 100-day moving average of $156.45. The stock also witnessed high trading volumes …
Yahoo Finance · 11/24/2015
Amgen Gained
In this part, we’ll see the moving averages of the holdings of the Health Care Select Sector SPDR ETF (XLV). As of November 24, 2015, 71% of XLV’s holdings were trading above the 20-day moving average, 66% were trading above the 50-day moving …
Market Realist · 11/25/2015
European Commission
Amgen (NASDAQ:AMGN) has earned an “A” credit rating from Morningstar. The research firm’s “A” rating indicates that the company is a low default risk. They also gave their stock a four star rating. Several other brokerages have also issued ... · 1 day ago
According to him, a deal between Amgen and Allergan can enable growth and provide multiple cost synergies. He said Allergan — with its strong portfolio, growth potential, and efficient management — is a good bargain … · 11/19/2015


AMGen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Locate…
AMGen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, AMGen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
Data from: Wikipedia